Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $5.56M rose 172.2% year over year, ahead of the +85.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 22.6% from the prior quarter. Over 3 fiscal years it compounded at +222.1% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +172.2% holds above the trailing-twelve-month pace of +85.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 15.31M USD
- Year-over-year change
- +88.1%
- 4-year CAGR
- +77.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.31M | +88.1% |
| FY2024 | 2024-12-31 | 8.14M | +1527.6% |
| FY2023 | 2023-12-31 | 500.15K | +9.2% |
| FY2022 | 2022-12-31 | 458.15K | -70.1% |
| FY2021 | 2021-12-31 | 1.53M | — |
Stock-Based Compensation vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 stock-based compensation of $18.83M is the largest of the 8 companies compared; the peer median is $2.17M.
- Its year-over-year change of +85.9% is the highest of 7, against a peer median of -28.4%.
- Over three fiscal years its annual growth of +222.1% compares with a peer median of +2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.83M | +85.9% | +222.1% | — | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $5.11M | +30.3% | -5.3% | 68.1% | |
| LTM Mar 2026 | $4.63M | -43.5% | +57.4% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $2.17M | +67.1% | +109.4% | — |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| LTM Mar 2026 | $0 | -100.0% | +7.0% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding IKT) | $2.17M | -28.4% | +2.6% | 38.2% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Depreciation & Amortization | 0 | 6.72K | 177.4K | 26.27K | 60.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.53M | 458.15K | 500.15K | 8.14M | 15.31M |
| Change in Working Capital | (1.76M) | 171.18K | 234.76K | 204.93K | 55.93K |
| Accounts Receivables | (110.14K) | 70.26K | 39.88K | 0 | 0 |
| Inventory | 1.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (630.9K) | 61.4K | (504.41K) | 271.78K | 146.83K |
| Other Working Capital | (2.33M) | 39.53K | 699.28K | (66.85K) | (90.9K) |
| Other Non-Cash Items | 721.63K | 67K | 31.54K | 0 | 5.05M |
| Operating Cash Flow | (14.3M) | (17.35M) | (18.09M) | (19.15M) | (27.79M) |
| Capital Expenditures | 1 | (243.26K) | (14.24K) | 0 | (13.4K) |
| Acquisitions (Net) | 0 | 243.26K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.73M) | (29.43M) | (60.46M) | (39.09M) |
| Sales of Investments | 0 | 4.96M | 41.1M | 23.45M | 41.6M |
| Other Investing Activities | 0 | (243.26K) | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.01M) | 11.66M | (37M) | 2.05M |
| Debt Repayment | (42.53K) | (248.91K) | 0 | 0 | 0 |
| Common Stock Issued | 41.14M | 44.14K | 8.54M | 103.48M | 108.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 848 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.09M | (204.77K) | 8.41M | 103.48M | 108.46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 26.8M | (33.56M) | 1.98M | 47.33M | 82.73M |
| Free Cash Flow | (14.3M) | (17.59M) | (18.1M) | (19.15M) | (27.79M) |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.